CureVac's amended patent survives BioNTech's challenge as EPO upholds validity. A German court will decide on infringement in ...

CureVac N.V. secured funding with GSK amid financial struggles, while a key patent win boosts stock. Click for why my ...

European Patent Office largely dismisses opposition filed by BioNTech SE in April 2023 challenging validity of EP 3 708 668 ...

Shares of CureVac climbed after the European Patent Office confirmed the validity of a patent that has been the subject of a lawsuit filed by BioNTech. The stock rose 7% to $2.99 on Friday. Shares ...

While BioNTech has evolved significantly since its ... The majority of these responses were poly epitopic directed against multiple mRNA-encoded neoantigens, and these responses were de novo ...

The court ruled that Pfizer and BioNTech must disclose any revenue gained from Moderna's patented technology, although the amount remains to be determined, and that they will pay extra.

U.S.-listed shares of BioNTech fell Monday, as the COVID-19 vaccine maker’s soft sales outlook offset better-than-expected quarterly results. The German company said it expects 2025 total ...

March 5 - Pfizer (PFE.N), opens new tab and BioNTech (22UAy.DE), opens new tab won a round in their legal battle with Moderna (MRNA.O), opens new tab over COVID-19 vaccine patents on Wednesday ...

March 10 (Reuters) - German COVID-19 vaccine maker BioNTech (22UAy.DE), opens new tab on Monday said that its 2025 revenues would likely fall to between 1.7 billion euros ($1.85 billion ...

European Patent Office largely dismisses opposition filed by BioNTech SE in April 2023 challenging ... invention of CureVac, called split poly-A tail technology, which enhances medical efficacy ...

Welcome to BioNTech's Fourth Quarter and Full-Year 2024 Earnings Call. I would like to hand the call over to Michael Horowicz, Director of Investor Relations. Please go ahead. Thank you.